This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Near Infrared Spectroscopy (NIRS) in Severe Sepsis (OTO-STS)

This study has been terminated.
(recruitment was stopped as consequence of cessation of funding (economic crisis))
Hutchinson Technology Inc
Assistance Publique - Hôpitaux de Paris
Information provided by (Responsible Party):
Djillali Annane, University of Versailles Identifier:
First received: September 9, 2005
Last updated: July 19, 2016
Last verified: July 2016
The purpose of this study is to evaluate the usefulness of an optimization of muscle perfusion and oxygenation, as assessed by the NIRS technique, in critically ill patients with sepsis.

Condition Intervention Phase
Critical Illness Severe Sepsis Device: Near Infrared Spectroscopy Device: conventional Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Study of Usefulness of Near Infrared Spectroscopy to Optimize Tissues Perfusion and Oxygenation in Severe Sepsis

Resource links provided by NLM:

Further study details as provided by Djillali Annane, University of Versailles:

Primary Outcome Measures:
  • A combined endpoint of mortality and sequential organ failure assessment (SOFA) score increase at day 7 is the primary efficacy endpoint [ Time Frame: Day 7 ]

Secondary Outcome Measures:
  • duration of mechanical ventilation [ Time Frame: from randomization to Day 28 ]
  • length of the hospital stay [ Time Frame: from randomization to Day 90 ]

Enrollment: 103
Study Start Date: July 2005
Study Completion Date: December 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Early goal directed therapy based on StO2 evaluation
Device: Near Infrared Spectroscopy
resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
Active Comparator: 2
Early goal directed therapy
Device: conventional
resuscitation will be based according to Surviving Sepsis Campaign

Detailed Description:

The systemic inflammatory response to sepsis may cause impaired tissue oxygenation that can persist despite the restoration of a normal hemodynamic profile and systemic oxygen transport.

Therefore, the assessment of tissue oxygenation and perfusion is recommended in patients with severe sepsis.

The InSpectra tissue spectrometer relies on continuous wave near infrared (NIR) technology to estimate non invasively local tissue hemoglobin oxygen saturation in tissue (% StO2). This technology had been tested in a variety of systems: standard theoretical models of light transport, isolated blood, isolated blood-perfused animal organs and healthy human volunteers with induced limb ischemia. In critical-care medicine, NIRS has also been used to evaluate muscle oxygenation in trauma resuscitation and in lower extremity and abdominal compartment syndrome. However, NIRS has been rarely utilised to measure tissue blood flow and oxygen uptake in critically ill patients.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Two of four criteria for the systemic inflammatory response syndrome; and one of the following:

    • systolic blood pressure =< 90 mm Hg; or
    • a blood lactate concentration => 4 mmol/l; or
    • skin marbling; or
    • impaired consciousness; or
    • urine output < 30 ml/h.

Exclusion Criteria:

  • Age < 18 years
  • Pregnancy
  • Do-not-resuscitate status
  • Advanced directives restricting implementation of the protocol
  • Obesity (body mass index [BMI] > 30)
  • Anasarca
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00167596

Raymond Poincaré Hospital
Garches, France, 92380
Hôpital Nord AP HM
Marseilles, France, 13
CHU Tours
Tours, France
Berlin, Germany
University Hospital Rostock
Rostock, Germany, 18057
NANAS Serafeim
Athens, Greece
EZAVALA Elizabeth
Barcelona, Spain
Sponsors and Collaborators
University of Versailles
Hutchinson Technology Inc
Assistance Publique - Hôpitaux de Paris
Study Chair: Djillali Annane, MD, PhD Raymond Poincaré Hospital, AP-HP
Study Director: Olivier Nardi, MD Raymond Poincaré Hospital, AP-HP
Principal Investigator: Gwenhael Colin, MD Raymond Poincaré Hospital, AP-HP
  More Information

Responsible Party: Djillali Annane, Professor in medicine, University of Versailles Identifier: NCT00167596     History of Changes
Other Study ID Numbers: 05008
Study First Received: September 9, 2005
Last Updated: July 19, 2016

Keywords provided by Djillali Annane, University of Versailles:
near infrared spectroscopy
tissue oxygenation
organ dysfunction

Additional relevant MeSH terms:
Critical Illness
Systemic Inflammatory Response Syndrome
Pathologic Processes
Disease Attributes processed this record on August 16, 2017